Finanzen von Insight Molecular Diagnostics Inc (IMDX)IMDXInsight Molecular Diagnostics Inc

Insight Molecular Diagnostics Inc (IMDX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pharma Services, accounting for 91.0% of total sales, equivalent to $217.49K. Another important revenue stream is kitted products. Understanding this composition is critical for investors evaluating how IMDX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Insight Molecular Diagnostics Inc maintains a gross margin of 65.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3815.06%, while the net margin is -4711.30%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IMDX converts its operational activities into shareholder value.

In the context of the broader market, IMDX competes directly with industry leaders such as HURA and BDTX. With a market capitalization of $141.37M, it holds a leading position in the sector. When comparing efficiency, IMDX's gross margin of 65.69% stands against HURA's N/A and BDTX's N/A. Such benchmarking helps identify whether Insight Molecular Diagnostics Inc is trading at a premium or discount relative to its financial performance.

The company reported a revenue of $239,000 for Q2 2026, indicating a transitional phase towards revenue generation despite ongoing losses. The gross margin of 65.69% shows potential for profitability as operations stabilize.